Bertin and Zymo Research Announce New Collaboration
Zymo Research Corp. and Bertin announce a collaboration that ensures the sample lysis step in the microbiome workflow is complete and unbiased. An application note is available describing the materials, procedure and results attained using the Precellys® Evolution Homogenizer together with the ZymoBIOMICS® Microbial Community Standards and ZymoBIOMICS DNA Miniprep Kit for purification of the DNA. Using both companies’ products, the researcher is afforded unbiased cell lysis in only one minute. The application note validates a procedure for accurate downstream microbiome measurements.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171207005711/en/
Picture showing the Precellys® & Cryolys Evolution tissue homogenizer equipment on the bench - Credit: T.Leaud
Zymo Research’s suite of ZymoBIOMICS® products addresses the complete Microbiomics workflow; from sample collection, DNA extraction, library prep, sequencing, through bioinformatics and final analysis. The ZymoBIOMICS® Microbial Community Standard contains three easy-to-lyse Gram-negative bacteria, five tough-to-lyse Gram-positive bacteria, and two tough-to-lyse yeasts. These accurately characterized microbial standards, enable the identification of exposure to artifacts, errors, and bias in microbiomics or metagenomics workflows, specifically 16S rRNA and shotgun-based sequencing approaches. Used in conjunction with the microbial standards, Zymo Research offers low-bioburden DNA isolation kits tuned for complete lysis of microbes with an innovative bead and buffer system.
Bertin has been in the sample preparation and homogenization instrumentation market for over ten years. Their line of Precellys homogenizers have won widespread recognition from the scientific community as hard-wearing, efficient and ergonomic research tools and have been cited widely in the literature. Initially designed for BSL-3 (Biological Safety Level) laboratories, the Precellys® Evolution makes it possible to efficiently homogenize a number of samples using an assortment of different-sized tubes, from 0.5 ml to 15 ml and it guarantees identical homogenization in each of the tube positions.
Bead beating is an accepted method to lyse various microbes but until now we have not been able to accurately assess the efficiency of the lysis. ”With the combination of Bertin’s homogenizer and Zymo Research’s Microbial Community Standard and DNA Miniprep Kit researchers and clinicians now have a rapid, complete homogenization procedure at their disposal ” said Marc Van Eden, Vice-President of Business Development at Zymo Research Corp.
Laurence Colin, Tel : +33 (0)1 43 59 00 46
ZYMO RESEARCH CORP.:
KIWI Communications, Inc.
Sheila T. Brann, Tel: +714.979.3464
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Lenovo Attains Status as Largest Global Provider of TOP500 Supercomputers25.6.2018 07:01 | Pressemelding
Today, at the International Supercomputing Conference (ISC) in Frankfurt, Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY) continued its global momentum, becoming the world’s largest TOP500 supercomputing provider measured by the number of systems ranked on the TOP500 list. 117 of the 500 most powerful supercomputers included in the TOP500 are Lenovo installations, meaning nearly one out of every four systems (23.4 percent) on the prestigious list is a Lenovo solution. “Last year, we set a goal to become the world’s largest provider of TOP500 computing systems by 2020. We have reached that goal two years ahead of our original plan,” said Kirk Skaugen, President of Lenovo Data Center Group. “This distinction is a testament to our commitment to prioritize customer satisfaction, deliver cutting edge innovation and performance and be the world’s most trusted data center partner. We are motivated every day by the scientists and their groundbreaking research as we work together to solve hum
XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 201825.6.2018 07:00 | Pressemelding
XebiaLabs, the recognized leader in Enterprise DevOps and Continuous Delivery software, today announced the release of The Periodic Table of DevOps Tools v.3, an update of its free, industry-recognized DevOps landscape tool. The latest release of this acclaimed tool features 52 new DevOps tools, a new design, and the addition of categories, such as Analytics and AIOps, to reflect the expanding DevOps tools and technologies market. In addition, users can select a tool in the Periodic Table and immediately visualize it in the software delivery pipeline using XebiaLabs’ integrated DevOps Diagram Generator. DevOps pipeline diagrams can be easily customized, downloaded, printed, and shared. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005106/en/ XebiaLabs Unveils “Periodic Table of DevOps Tools” v.3 at DevOps Enterprise Summit London 2018 (Graphic: Business Wire) Given the fast pace at which new DevOps tools become availa
Enterprise DevOps for the Cloud25.6.2018 07:00 | Pressemelding
XebiaLabs, the recognized leader in enterprise DevOps and Continuous Delivery software, today announced a DevOps framework that provides a smooth pathway to the cloud for companies who are moving applications to cloud-based resources on a large scale. The framework connects enterprise DevOps practices with common cloud management functionality and provides an essential foundation as enterprises accelerate their transformations to cloud-based applications. Cloud Does Not Equal DevOps Easy access to public cloud technologies creates a common misconception: moving to the cloud will not only provide more flexible and scalable infrastructure at a lower cost, but it will also accelerate the delivery of applications to the customer. In reality, moving to the cloud is just one step in that journey. Enterprises that are looking to improve and accelerate software delivery are implementing DevOps practices that span the entire software delivery value stream. These practices are generally unrelate
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,